Interferon β-1b Treatment in a Korean Girl with Multiple Sclerosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Here we report a case of pediatric multiple sclerosis treated with interferon β-1b. Interferon beta is widely used in adult patients with multiple sclerosis (MS). However, its effects and safety in pediatric patients have not been well established. Although supporting data are limited, the use of disease modifying therapies (DMTs) such as interferon β-1b is recommended early in treatment of children with MS. Reports of interferon beta treatment in pediatric MS patients in Korea are rare. In this report, we describe a Korean girl who was effectively treated with interferon β-1b for three years. There were no relapses or serious side effects. Therefore, this report provides evidence supporting the use of interferon beta in pediatric MS patients in Korea and other Asian countries. We also reviewed current medical treatment of MS, including some DMTs and second-line treatment options such as natalizumab and cyclophosphamide, and several new oral agents such as fingolimod.
Abstract
Here we report a case of pediatric multiple sclerosis treated with interferon β-1b. Interferon beta is widely used in adult patients with multiple sclerosis (MS). However, its effects and safety in pediatric patients have not been well established. Although supporting data are limited, the use of disease modifying therapies (DMTs) such as interferon β-1b is recommended early in treatment of children with MS. Reports of interferon beta treatment in pediatric MS patients in Korea are rare. In this report, we describe a Korean girl who was effectively treated with interferon β-1b for three years. There were no relapses or serious side effects. Therefore, this report provides evidence supporting the use of interferon beta in pediatric MS patients in Korea and other Asian countries. We also reviewed current medical treatment of MS, including some DMTs and second-line treatment options such as natalizumab and cyclophosphamide, and several new oral agents such as fingolimod.
참고문헌 (15)
- Banwell B, "Multiple sclerosis in children: clinical diagnosis, therapeutic strategies future directions", Lancet Neurol, 6, pp.887~902 (2007)
- Chitnis T, "Consensus statement : evaluation of new and existing therapeutics for pediatric multiple sclerosis", Mult Scler, 18, pp.116~127 (2012)
- Ghezzi A, "The management of multiple sclerosis in children : a European view", Mult Scler, 16, pp.1258~1267 (2010)
- Banwell B, "Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis", Neurology, 66, pp.472~476 (2006)
- Kim NH, "Prevalence of multiple sclerosis in Korea", Neurology, 75, pp.1432~1438 (2010)
- Lim BC, "Relapsing demyelinating CNS disease in a Korean pediatric population : Multiple sclerosis versus neuromyelitis optica", Mult Scler, 17, pp.67~73 (2011)
- Ghezzi A, "Safety and effectiveness of natalizumab in pediatric multiple sclerosis: results of 17 patients", MultScler, 15(Suppl2), pp.774~ (2009)
- Makhani N, "Cyclophosphamide therapy in pediatric multiple sclerosis", Neurology, 72, pp.2076~2082 (2009)
- JoepKillestein, "Oral treatment for multiple sclerosis", Lancet Neurol, 10, pp.1026~1034 (2011)
- Kim SH, "Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?", Mult Scler, 10, pp.1480~1483 (2012)
- Lucchinetti CF, "Risk factors for developing multiple sclerosis after childhood optic neuritis", Neurology, 49, pp.1413~1418 (1997)
- Bonhomme GR, "Pediatric optic neuritis : brain MRI abnormalities and risk of multiple sclerosis", Neurology, 72, pp.881~885 (2009)
- Morales DS, "Optic neuritis in children", J Pediatr Opthalmol Strabismus, 37, pp.254~259 (2000)
- Renoux C, "Natural history of multiple sclerosis with childhood onset", New Engl J Med, 356, pp.2603~2613 (2007)
- Amato MP, "Cognitive and psychosocial features of childhood and juvenile MS", Neurology, 70, pp.1891~1897 (2008)